@article{article_498721, title={Long-term follow-up of non-diabetic obese children and adolescents treated with metformin}, journal={Turkish Journal of Clinics and Laboratory}, volume={10}, pages={57–61}, year={2019}, DOI={10.18663/tjcl.498721}, author={Keskin, Melikşah and Aycan, Zehra and Işın, Uğur Ufuk and Çetinkaya, Semra}, keywords={Obezite,insülin direnci, Çocukluk dönemi}, abstract={<p class="MsoNormal" style="text-align:justify;line-height:150%;"> <b> <span lang="en-us" style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;" xml:lang="en-us">Aim: </span> </b> <span lang="en-us" style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;" xml:lang="en-us"> Childhood obesity is an important public health
problem with increasing prevalence.Type 2 diabetes mellitus(T2DM) is strongly
associated with obesity and metabolic syndrome. Adressing obesity and insulin
resistance by drug treatment represents a rational strategy for the prevention
of T2DM. </span> <span lang="en-us" style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;border:none;" xml:lang="en-us">The aim of our study was to evaluate the
one year metformin treatment’slong-term effectiveness in children and
adolescent. </span> <span lang="en-us" style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;" xml:lang="en-us"> </span> </p> <p> </p> <p class="MsoNormal" style="text-align:justify;line-height:150%;"> <b> <span lang="en-us" style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;border:none;" xml:lang="en-us">Material
and Methods: </span> </b> <span lang="en-us" style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;border:none;" xml:lang="en-us">Patients who were diagnosed with obesity </span> <span style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;">(VKİ>+2
SDS) </span> <span lang="en-us" style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;border:none;" xml:lang="en-us">and found to have insulin resistance
(total insulin at OGTT >300 mIU/ml and homa-IR >3.4)and other obesity co-morbidities, agedbetween
10-18 years, treated with metformin in addition to lifestyle change for a year and
with regular follow-up for a minimum of 2 years after metformin treatmentin our
clinicwere included inthe study. <b> </b> </span> </p> <p> <b> </b> </p> <b> </b> <p class="MsoNormal" style="text-align:justify;line-height:150%;"> <b> <span lang="en-us" style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;border:none;" xml:lang="en-us">Results: </span> </b> <span lang="en-us" style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;border:none;" xml:lang="en-us">A total of 12 cases including 8 girls with
a mean age of 13.2±2.1 years and mean follow-up duration of 3.9±1 years were
included in the study. While the body mass index (BMI) of the cases at
presentation was 31.2±5.6 kg/m <sup>2 </sup> and BMI-SDS was 2.7±0.7, the BMI-SDS
value after one year of metformin treatment was found to have regressed to 1.9±1
(p:0.04), and the BMI-SDS value two years after the interruption of metformin
treatment had increased to 2.1±1.04 but was not as high as the period before
metformin treatment (p:0.033). <b> </b> </span> </p> <p> <b> </b> </p> <b> </b> <p class="MsoNormal" style="text-align:justify;line-height:150%;"> </p> <p class="MsoNormal" style="text-align:justify;line-height:150%;"> <b> <span lang="en-us" style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;border:none;" xml:lang="en-us">Conclusion: </span> </b> <span lang="en-us" style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;border:none;" xml:lang="en-us">One-year metformin treatment improved the
BMI SDS and homa-IR values of the obese children and this improvement decreased
but continued in the second year after the discontinuation of the treatment. <b> </b> </span> </p> <p> <b> </b> </p> <b> </b> <p> </p>}, number={1}, publisher={DNT Ortadoğu Yayıncılık A.Ş.}